Welcome to the Royal Philips Q4 and Full Year 2022 Results and Creating Value with Sustainable Impact Conference Call on Monday, 30th of January 2023. During the call, hosted by Mr. Roy Jakobs, CEO, and Mr. Abhijit Bhattacharya, CFO, all participants will be in a listen-only mode. After the introduction, there will be an opportunity to ask questions. Please note that this call will be recorded and replay will be available on the Investor Relations website of Royal Phillips. [Operator Instructions]

Hi, everyone. Welcome to the Philips' fourth quarter and full year 2022 results webcast. I am here with our CEO, Roy Jakobs, and our CFO, Abhijit Bhattacharya. We're also joined today by Shez Partovi, Chief Strategy and Innovation Officer; Wim Appelo, Chief Operations Officer; and Francis Kim, Head of Quality. I would like to first go through the agenda for today's webcast. We will start with a discussion of our fourth quarter and full year 2022 results. We will then talk about how we will create value with sustainable impact with presentations about our focused organic growth and scalable innovation strategy and our three execution priorities: Patient safety and quality, supply chain and operating model simplification. We will wrap up with our value creation trajectory. We will have a session of around 70 minutes, followed by Q&A. The press release, slide deck and frequently asked questions on the Respironics recall were published on our Investor Relations website this morning. The replay and full transcript of this webcast will be available on the website as well. Before we start, I want to draw your attention to our safe harbor statement on screen. You will also find the statement in the presentation published on our Investor Relations website. With that, I'll hand over to Abhijit.

Thanks, Leandro. Good morning, and welcome, everyone. Let me start with our group performance and profitability in the quarter. Comparable sales growth was just over 3%, driven by improved component supplies in particular, in hospital patient monitoring, Image-Guided Therapy and Ultrasound. We delivered growth of 5% for Diagnosis & Treatment and Connected Care businesses on a comparable basis, which was partly offset by a decline in Personal Health due to China and Russia. Although the component supply situation is improving, the situation remains challenging, as we anticipate gradual improvements during the year. Adjusted margin was 12%. We continue to see a significant component and wage inflation, which had a 370 basis points impact on our margin. This was in part offset by our pricing and productivity actions, which contributed a further 260 basis points. As I've explained before, the positive impacts -- positive pricing impacts on our health systems businesses, that is Diagnosis & Treatment and Connected Care, will be reflected in the profit and loss account during the second half of 2023. The adjusted EBITA margin was 11.3% in Diagnosis & Treatment, 12.6% in Connected Care and 17% in Personal Health in the fourth quarter. In the quarter, our operating cash flow was €540 million and free cash flow was €301 million. Accounts receivables increased in the quarter, driven by the strong sales in the month of December, which we expect to convert to cash in 2023. We won a further 35 new long-term strategic partnerships across our regions, bringing the total to close to 100 in 2022. This is a core part of our growth strategy and improves the quality of our recurring revenues. Now, moving on to the segment highlights from this quarter. In Diagnosis & Treatment, comparable sales increased 5% in the quarter, driven by high…

Thank you, Abhijit, and thanks, everyone, for joining us this morning. I'm Roy Jakobs. And as you know, I was appointed as President and CEO of Philips last October. I'm honored to have been given the responsibility to lead Philips, and I look forward and commit to a transparent and constructive engagement with you and all our stakeholders. There is no denying, 2022 was a tough year here at Philips, and that is also reflected in the financial performance that Abhijit just presented. As you all get to know me better, you will see a few things. First, I'm a realist. And right now, it's very important to lead with realism. I'm also a great believer in knowing where I want to go and having a clear plan to get there, a plan that people can understand and have confidence in. Right now, Philips needs a clear strategy and a clear plan focused on execution. And thirdly, you will see, I like to take on a challenge. Right now, I could not be more excited about the future of this company as we not only face down the tough challenges, but also face up to the enormous opportunities for all of us at Philips. And I'm very passionate about working in a company that serves patients and people. Like many of you, I've been a patient. For several years, at a young age, I experienced first-hand the importance of good health and good health care. I understand the need to improve the outcomes for patients, and that's a huge motivator for me. Since taking up the role in October, I've spent every minute, exposing, examining and exploring our challenges and opportunities. To tackle these challenges and opportunities, Philips must change. And making that change is what excites me and will…

Thank you, Roy. At Philips, we have a long heritage of leadership in innovation. Our plan is to build on that strength to achieve even greater impact for patients and customers. For years, Philips has had a large corporate research function that has led to the launch of historically successful new products. In the past, when the life cycle of health care transformation was slower, a functional approach to innovation was reasonable. In that model, innovation was mostly technology forward. Innovative ideas emerge from corporate research and move from one function to the next in a step-wise fashion until it reached the end customer. However, recent industry trends have accelerated technology adoption life cycle within health care. As a leading health tech company, we are embracing this trend and shifting how we innovate to deliver impactful outcomes in an industry with rapidly changing end customer expectations, innovation must start with the end customer and work backwards. In other words, we must innovate on behalf of patients and customers. To do that, we will move innovation into the heart of the business by bringing all components of innovation to the same leadership roundtable under one accountable leader, and focused on patient safety and quality by design. In this new model, innovation is business-led and closer to the customer segments we serve. In addition to bringing patient and customer centricity to our innovation model, we will also focus on fewer, better resourced, more impactful initiatives so we can scale them. We will sustain our significant R&D commitment, but retarget efforts towards high-impact areas that align with our strategic objectives. Practically speaking, that means pruning products and projects that are not aligned with our scaling ambitions and instead doubling down on our strengths in the customer segments we lead. This plan will be…

Good morning. I am Francis Kim, and I lead the quality and regulatory function. As Roy said out earlier, patient safety and quality is our highest priority. Today, I'd like to explain how this translates into changes we have made and we'll be implementing to our personnel, structure and approach. Firstly, we're enhancing patient safety and quality by continuing to drive a cultural shift, ensuring a greater level of accountability within the business. We are elevating leadership to the executive committee and holding all business leaders directly accountable for patient safety and quality within the businesses they run. This involves continuous and deep engagement with quality, regulatory and clinical functions. Moreover, patient safety and quality is now a KPI for all employees structurally embedded into the performance appraisal process. We continue to strengthen our competencies to ensure we have the best team in the industry. This includes recruiting more quality regulatory clinical and medical device experts across the enterprise. We are making progress, however, we fully acknowledge there is still much more work to do, which is why we view our efforts as a multiyear journey and have expanded our patient safety and quality program. Our next major area of focus is to ensure that all product design starts with a patient safety and quality in mind to avoid further issues. Technology has been one of our core strengths at Philips. Going forward, as Shez has mentioned, we need to make sure that our great product innovation starts with a patient-centric lens. Over 70% of the issues we faced in the past few years have been design-related. Therefore, our primary task has been to ensure the design process is extremely robust. This means, linking product development from inception with a patient view and the highest product performance requirements embedded throughout.…

Thank you, Francis. Hello, everyone. I'm Wim Appelo. I've recently joined Philips and taken on the role of Chief Operations Officer. Before this, I held several roles in the medtech industry and before that, in the technology industry. Let me give you an update on the current supply chain situation. Five years ago, in the context of a changing business portfolio, Philips centralized a functional supply chain organization at the enterprise level. Over the years, the structure [delivered] (ph) value by creating common practices and capturing cost efficiencies for Philips. It created multimodality manufacturing sites, shared innovation and excellence, standardized product development and processes. However, in recent years, our industry has seen a number of extraordinary headwinds, including significant disruptions due to COVID, markets that are becoming more and more volatile, global supply chain disruptions and, in particular, e-component shortages and supplier decommits. These headwinds severely challenged our internal functional structure and led to an accumulation of issues, impacting our agility and resilience, suboptimized information flows, compounded by a broad and complex product portfolio. As a result, the delivery of our health systems has suffered delays, increased backlogs and inventory levels, and thus, our customers have been negatively impacted. To ensure reliability of delivery for our customers going forward, we have taken a close look at our supply chain and have concluded that we need to change on three fronts: our end-to-end supply chain setup; our products and processes; and third, our supplier management. With respect to supply chain setup, the current environment requires agility and resilience in each individual business. Therefore, as of April this year, we're moving to a customer-centric end-to-end supply chain teams. These are going to be closely aligned to the different businesses we operate and with dedicated leaders for each individual business. It will help…

Thanks, Wim. I want to give additional color on the simplification of our operating model that I explained earlier. Our goal is to remove complexity and become much more focused on strategy and innovation execution. We will organize around our business segments, supported by strong regions and leaner functions at the center. These businesses will have end-to-end accountability, including sales and services, direct supply chain support and more integrated patient and people-centric innovation resources. This will also include the difficult, but necessary further reduction of our workforce by an additional 6,000 roles globally by 2025. 3,000 will be implemented in 2023. This is in addition to the reduction of 4,000 roles announced in October 2022. This change and these reductions will help make Philips more agile, more competitive and ultimately result in supporting better outcomes for our customers, and a simpler, more productive and more engaged workplace for employees, motivated and attracted by our purpose. To enable this, a renewed culture will be built at Philips, focus on our core purpose, transparency, being patient and people-centric and where we have all clear capabilities and feel fully empowered. We are also strengthening our teams with new technology talent, including seasoned leaders with deep domain expertise and will include changes to our executive committee. I mentioned that we have elevated the patient safety and quality function to the executive committee level. Steve C. De Baca has been appointed as new Chief Patient Safety & Quality Officer, a member of the Philips Executive Committee effective February 6. Steve brings more than 30 years of quality and regulatory affairs experience in the health technology industry. Additionally, Jeff DiLullo, a leader from within Philips, has been appointed as the new Chief Market Leader of Philips North America. Jeff brings fast experience in customer and service delivery, enterprise account management and government relations to drive growth in this very important region for Philips. Jeff will succeed Vitor Rocha, who has decided to leave Philips. We also expect to announce the new leaders for Precision Diagnosis businesses as well as the Connected Care businesses in early 2023. And here, you have the experienced and highly motivated team that creates and owns this plan together. With that, I would like to call back Abhijit to the stage to take us through the financial details of our value creation plan.

Thank you, Roy. Let me now take you through our value creation path. And as Roy mentioned earlier, you saw on this slide, it's a progressive part in three phases. 2023 is when we lay the foundation. You'll then see an improvement and an acceleration in performance during the period '24 and '25, and then moving to the full delivery on our full potential in 2025. For this year 2023, as I guided earlier, you will see low single-digit growth, high single-digit EBITA and a free cash flow of between €0.7 billion and €0.9 billion, that moves in the 2025 phase to a cash flow above €2 billion moving to the higher range of the mid-single-digit bandwidth and moving profitability to the mid- to high-teens. What I'll do now is take you a little bit more in detail on each of the segments. So, if you look at Diagnosis & Treatment, you see that the growth rate will be in the mid-single digit, but progressively increasing over time. You see the same for Connected Care. And Personal Health, as I mentioned, will have a low single-digit growth this year, returning to mid-single-digit growth over the period from '24, '25 and onwards. You will see across all clusters an improvement in the EBITA margin, and you will also see that Diagnosis & Treatment moves from the low-teens to the mid-teens, and then Connected Care moving also from low teens to the high teens. Personal Health is already in the high teens and will improve this year over last and continue in that journey in the high-teens. This will -- this improvement in profit trajectory will be driven in a big part with productivity initiatives that we have taken. And we have stepped that up from the €1.5 billion to €2 billion.…

Thanks, Abhijit. So, let's move to conclude, and let me summarize where we are and where we are going. Then, we will have time for your questions. When I spoke earlier, I said that it's important to lead company with realism right now. The approach we have taken and presented to you to the strategy and plan is to be realistic. And with the team around me, I am both confident as well as excited for the roadmap we have laid out for you to deliver the change and to create growth and value. We have the determination and we are and I am committed to improve the performance and fully capture Philips' potential. So, let me remind you how we will create value with sustainable impact. Philips operates in attractive, growing markets and holds leading positions in key segments. Our portfolio is very well positioned to take advantage of the growth and margin opportunities in the segments where we operate. The combination of strong customer relationship and established trusted brand and purpose gives us a compelling platform to build on. But the opportunities can only be realized if we confront the structural challenges facing us. And we are ready to do that. Our strategy and plan to focus on segment leadership positions, adopt a patient and people-centric approach to innovation, radically simplify how we work and execute patient safety and quality, top of mind are the ingredients that will drive change and create value with sustainable impact. And the oil that will lubricate this process is operational excellence and disciplined execution. We look forward to being a force of innovation and change in a world where making a difference has never been more important. I would like to thank you for being with us. We will be back to take your questions in a couple of minutes.

[Operator Instructions]

Welcome back, everyone. Let me hand over to the operator for Q&A.

Thank you. We will go to our first question. And your first question comes from Ms. Veronika Dubajova from Citi. Please state your question.

Hi. Good morning, and thank you guys for taking my questions. I have two, please. One, Roy, would just love you to hear a bit more from you on the operational and organizational changes that you're making within the company. In some ways, as a long-term follower of Philips, it strikes me like we're moving a little backwards in terms of what the organization looks like and the supply chain and R&D sitting more within the individual businesses. Just would love to get your thoughts on why that's the case. Maybe some of the risks that you see to the business as you kind of implement this plan and to what extent they're reflected in the guidance in '23 and '24, and just conceptually kind of how you're thinking about this change? And then, my second question is, please, if you can just give us an update on where you are with the consent decree and DoJ discussions? And to what extent you'd expect or when we might expect an update from you on that? And how much longer you think that process might take? Thank you so much.

Thank you, Veronika. Let me start with the first question. So, when we look at the simplification of the organization, we're responding in first place, also to what we have heard from our employees. We have become too complex both in terms of how we have been setting up as well as the processes that we run. So, there's a real need and opportunity to make it simpler for all of us to work. And what we do actually will make very clear single accountability and bring that to the businesses. And they will be supported by leaner functions and strong regions where we have the customer-facing interactions. So, we're moving from a phase where we have been functionalizing quite strongly towards actually going more integrated about winning in specific segments and making sure that the segment is set up to win. Take an example, in the exciting area of Image-Guided Therapy, which we have a leadership position, we actually have strong plans to grow further. Now that means that you really need to focus on how do you serve those customers the best. Therefore, actually, we bring the innovation forward into the business to more closely where the customers innovate. Secondly, IGT has also its own supply chain demands, because it's very different if you orchestrate your supply chain to deliver a complex system in cath lab like in Azurion versus if you, for example, deliver a toothbrush to a consumer. So, we're actually making sure that the supply chain is integrally organized around the specific demands for that segment. We're also putting patient and people-centric innovation in that business and making sure that the quality norm is exactly for what you need to do. And again, there are differences across the different that we serve. So actually, where we're moving towards is really winning in all these strong portfolio elements that we have, but doing it with the rules of the game of that specific segment. And then, your second question on the consent decree, we are in continued dialogue with the regulating that. So therefore, it's too early currently to disclose what any outcome could be. Of course, we know how important it is for all of you and also for us. So, when we have news, you will be the first one to be updated on that. In a similar fashion, actually, it's about the litigation. We're also there, still in the early phases. There is nothing that we can say currently about any quantification of potential impact. We also know that that's something that you are very eager to learn about, as do we. But in the process of the discovery of the litigation and actually then leading up to the consequences, we are not yet in a position to disclose that. But we will hope to do that in the second half of this year.

Understood. Thanks, Roy. And maybe just as you've done the structural review of the company, I kind of wonder what your commitment remains to the Sleep & Respiratory business, and how you think it fits into the broader portfolio at Philips, and is this something that still makes sense for the business to retain?

Yes. As you saw earlier in my presentation, so when looking at Philips, actually, we have refocused the portfolio. And the portfolio we have actually, I think, is a very strong and compelling portfolio, and that is including the Sleep & Respiratory Care business. If you look to the fundamentals of that business, we know that actually sleep apnea, as a disease, as something that needs to be treated, is still growing in size. Patients still are in need for more treatment and we are in that segment, the second player. We are still the second player. So actually, we see a role for us when we work through remediation of the recall work also through potential consequences that [the CD] (ph) might bring to restore our business position, because this is something that really fits what we are good at is bringing innovation to patients in the home but also in hospital settings.

Understood. Thank you, guys. I'll jump back into the queue.

Thank you. We will now go to our next question. And your next question comes from the line of Hassan Al-Wakeel from Barclays. Please go ahead. Your line is open.

Good morning. Thanks for the presentation and taking my questions. I have a couple, please. Firstly, on the outlook for 2023, could you talk about how you are thinking of the year in terms of supply constraints, particularly given a strong exit rate in Q4 2022? Is it fair to assume that this is not a stretch target in the way that Abhijit has guided and talked about in the past, but maybe a more conservative or realistic one? Secondly, could you talk a bit about the Sleep & Respiratory Care assumptions for this year in terms of revenues and margins? And whether you are assuming a consent decree that is broader than just systems and encompasses all of Respironics? Thank you.

Thank you. Let me maybe start with the first one. So, as I presented today, we are and I have put out a realistic outlook, and that's what you see reflected in the plan for 2023. We were happy to see what happens to order book conversion, like in Q4 if we get more supply. And we will work very hard to get more supply so that we actually see that continued in 2023. And that's also what we have built into the plan. But it's also fair to say that we are not yet at a point that we can count on that all the time. That's so reliable and so predictable that we already have the full year outlook on our supply chain and the supply chain availability to underpin an even stronger plan that we have presented. So, we go in with a realistic plan. We will take our measures to improve the supply chain and also the other measures that we presented. And then, actually, we'll come forward step by step in terms of how we deliver on the plan. Secondly, if you talk about the SRC assumptions, you have seen that what we included in the guidance is that we said for SRC, we have taken the base assumptions that we also took last year in terms of the outlook that we currently hold, which is a 10% CSGR. And in that, we have a modest assumption of low single-digit growth and a breakeven assumption for 2023. So that's the grounding of the plan, also as we don't know yet what the constant degree will have as a potential further impact to this.

Roy, it's very helpful. And if I can squeeze in one other on the order book. Could you talk about the rationale for canceling orders and which modalities these were for? Given the order book was flattish, excluding this globally as well as in the U.S., are you concerned about the state of U.S. hospitals?

So maybe two answers to that. First, we have been looking at the quality of the order book and where we have been going in is especially in all orders that have and were older, because they were actually contracted at earlier pricing as well as the lead times for them are long. If you look into specifically where it was and good area, as an example, is the MR. We have a lead time that is over a year. So that means that actually also in this area, we have long lead times for our customers, as well as then if you take the pricing that we had from the past, that actually has a negative effect. So, we combined both and said, okay, if we go back to the customers, but then also work on the quality of our order book, actually, we take lower margin orders out, strengthen the order book in terms of what we can deliver and when, and therefore, we have a better strength of the overall order book that we have. If you look at the American hospital system, and I think you have seen how they have been trending, we do put a bit more cautious outlook on the spend profile for 2023 that they will have. We believe that they are under tremendous pressure. They have huge staff shortages. They are also dealing with the inflation. At the same time, they also still need to catch up from the technology that they need to kind of invest in that they did not invest in during COVID. So, there are multiple trans playing, but therefore, we are cautious on the immediate outlook. We do think that mid-term, it will pick up again. And also, if you look to the order book that we have, we can still actually generate an attractive growth there, but we do -- we are mindful of the state of affairs in the U.S.

Perfect. Thank you.

Thank you. We will now take our next question. And your next question comes from the line of David Adlington from J.P. Morgan. Please go ahead. Your line is open.

Good morning, guys. Thanks for the question. Just also on the orders, I just wanted in terms of cancellations, what customer reaction to those cancellations was and where they were going in terms of trying to source those canceled orders? And then, secondly, just in terms of the dividend, I just wonder what your plans are on turning to the cash dividend, why put in place a full scrip dividend? Thanks.

Thank you, David. Maybe Abhijit, you want to take the question on the orders?

Yes, I can. I think also following up on what Hassan was asking, this is largely in the domain of Diagnosis & Treatment, where we have -- I think we have had good dialogue with the customers because these orders were taken long back. They were not at the margin generation that we were expecting. So, it has been done in collaboration with the orders. Regarding the scrip dividend, I think given that last year, in 2022, our cash flow was negative, and for a number of reasons, which I just explained in the presentation, first, we had a lower income, the buildup of our inventories, as well as the one-off costs related to the Respironics recall, it puts us in a position where we don't want to further pay out cash in terms of dividend for this year. So, we have, therefore, taken this plan to make it a scrip dividend. And then, as we see how it develops during the course of the year, we will see how we decide on this going forward.

Perfect. Thanks. And then, just a follow-up. Just in terms of, I think, it was €60 million litigation in the fourth quarter, I just wonder if you'd tell us what that related to?

Yes. It's not related to the Sleep recall. It's an old litigation that was on and we have -- we expect to come to a settlement of around that amount and, therefore, we have provided for it. But it has nothing to do with the Sleep recall, if that was type -- intent of the question.

Okay. Thank you.

Thank you. We will now go to our next question. And the next question comes from the line of Graham Doyle from UBS. Please go ahead. Your line is open.

Good morning. Thank you for taking my questions. It should be two for me. So, just firstly, on sort of phasing, I suppose. So, you obviously had a really high conversion rate in Q4 '22, given revenues were up and order book down. But you're pointing towards a sort of a slower Q1 and then order conversion improving through the year in '23. So, is it reasonable to assume that there is a slower or weakened order conversion in Q1 versus Q4? Is there any reason there was some pull forward of revenue there, I suppose? And then, second question relates to ozone testing. You've been pretty helpful in the detail you provided in the past. And obviously, today, you've given us a bit of a timeline for testing results. But one of the things you disclosed in December 21 was the level VOCs being measurable at cycle 200, I suppose having run through it again. Is there -- you did the same cycle and I presume the same testing at the cycle 500. So, it'd be good to know what happened beyond cycle 200. So, that VOC level, did that change once you went past cycle 200? It would be great to know that given the test should have been run. Thank you very much.

Maybe let me take the first one, Graham. So, the conversion rate, what we have also said on Q1, with the slow start, we have indicated that the health systems businesses, so Diagnosis & Treatment and Connected Care, which are built off the order book, they actually start also with good growth. The issue is in Personal Health, we start with a decline, because last year, we had a strong growth of 8%. We had a 17% growth in North America. So, there is a bit of that comparables that play. And of course, the China situation does not improve in Q1. So, we have lower sales in Connected Care, and we have lower sales in license revenue, and that is causing the kind of slower start that we have indicated for Q1. Let me hand over to Roy on the testing.

Yes, let me take the testing. So, indeed, we have shared encouraging testing results in December, including the details that also part of the deck that we shared. The ozone testing is still due. As we shared earlier, we hope to disclose the data in due course early 2023. Actually, we are also there positive on what we are seeing, but we need to run through the full cycle. And most importantly, we also want to do it in, again, good alignment with the regulator before we bring out the data. So, we are testing all the cycles, so including indeed the 200 and beyond. I do not want to pre-empt the results, because we will disclose them when we also have discussed that and in alignment with the regulator. But I can tell you that we are positive on it and kind of we will come back to you when we are able to share.

Okay. Thank you very much. Just a quick follow-up on the order book, actually. Just the sort of trimming that was done in order to, I suppose, reprice and improve the quality of your order book, is there any more of that to do or do you feel like you've kind of gotten through that?

No, we have done that. So that is done. It was a onetime cleanup that we did, and that's the end of it.

Okay. Great. Thank you very much, guys.

Thank you. We'll now go to our next question. And your next question comes from the line of Falko Friedrichs from Deutsche Bank. Please go ahead. Your line is open.

Thank you very much. Good morning. My first question is whether you can update us on your latest thinking about your return to the market in your Sleep Care business? And when you think you can be back to your previous market shares? And then, my second question is on the definition of your low-teens adjusted EBITA margin target. Does that mean 10% to 13%? I'm asking because for some people, low-teens are starting at 13%. So, would be great to clarify that. Thank you.

Okay. Let me take the first and then probably Abhijit can take the second. So, as we shared, the first priority for the Sleep & Respiratory Care business is finalizing the recall. So, we have all our efforts on that. And we were encouraged and also, as you saw, as promised, we got to the 90% produced in end of 2022. We now want to bring that to 100% for sleep therapy devices by end of Q1 so that then we can ensure all patients will get the devices, whilst we also then need to work through the respiratory side. Now that, in combination with the dialogues that we currently have with the regulator, will determine when we can go to market. As these dialogues are ongoing, we don't want to kind of get ahead of us and get ahead of that in terms of coming out with any specific detail around that. As shared, whenever we have that outcome, we will immediately come back to you. For the moment, the first priority is really finalizing the recall, and we have all our efforts and resources focused on that, as well finalizing the testing, as you have seen, because we know how important that is for patients, and then also working through any other consequences so that we can restore in full the market position that we had. Now, I think it's realistic to say that this will take a bit of time because of the position that we are in, but we are really determined to get back to where we were.

Yes. And on the second one, we have taken 11% to 13% as the low teens range, just to clarify, Falko.

Okay. Thank you.

Thanks.

Thank you. We will now go to the next question. And your next question comes from the line of Sezgi Oezener from HSBC. Please go ahead. Your line is open.

Hi. Thanks for taking my questions, and thanks for the presentation. The first one is on the 4,000 plus now 10,000 -- plus 6,000 now 10,000 of personnel that you have decided to reduce. We see that in the last quarter since you've announced the 4,000, the number came down roughly by 2,000. So, what's the timeline for the rest of the 4,000? I know for the 6,000, you said 3,000 will be reduced in 2023. So, the rest of this, and also the breakdown from the different departments, where do you expect this reduction to be more? And post this reduction, what kind of wage inflation are you calculating? And my second question relates to the insurance payoff for the product liabilities. You mentioned in the past that you had some insurance on the products. I know that you don't have an estimate of the legal liability or the other legal costs that come with the recall, but do you have an estimate on the insurance liability, and how that adds up for you? And the last one will be, you mentioned that you've shifted the R&D more from commercial to the business sides. Could this have a negative impact in terms of reducing the synergy that you extract from this? Thank you.

Thank you, Sezgi. Let me take the first and third question, and then Abhijit can take the second. So, let me be very clear on the reduction of force. And let me also again stress how painful it is but how necessary it is, and that we will, of course, execute this with the most respect and also with best care for our people, trying to get them to other workplaces, and we need to give them a plan that goes with it. Now, if you look to the numbers, I announced in Q4 that we would reduce 4,000. Of those, we have executed 3,000 in 2022. Then, today, we announced another 6,000. Of that 6,000, we will do 3,000 in 2023. If we then take the remaining 1,000 of 2022, it will mean that we have another 4,000 that we will have to reduce this year. It also means that of the total, we have 3,000 remaining, which we'll do in '24 up to '25. There is a phasing that actually relates to the first interventions that we are taking now as announced in 2022, it was a generic reduction across the organization. We're now going very targeted with the shift of model. We indeed take on the functions, in particular, to lean out the organization and bring more into the business, but also strengthen the regions. And then, we have a shift in innovation model that also plays part, but that's also a big part of shift of resources more into the businesses. And that ties into your second question. We were doing 30% of our investment in research or in R&D in corporate research. Now, we are shifting that to doing 90% in the business. We still will have €1.7 billion of investment in innovation. So, innovation is the core of what we do, will remain core to what we do. But we want to get it closer to the customer so that we increase the innovation cycle and make it as patient and people centric, but also, we want to get better returns by doing fewer projects and scale them more. So that's actually what we intend to achieve with this different approach to innovation. So, we expect actually to have even more relevant and impactful innovation to deliver to our customers, to our patients and our consumers, but doing it in a more efficient manner while still spending above industry on innovation. Maybe you can take a second.

Yes. On the liability insurance, we have mentioned earlier, we have a coverage, which would be between the €500 million and €600 million. Now, of course, if you don't know the liability, it becomes more difficult to settle with the insurance companies. So that's a dialogue that will still continue. And once we have, let's say, clarity on that, we will again come back to you and make it clear.

And maybe on the third question, let me give you a concrete example how this will work. So, if you think about one of the very exciting areas that we are operating in is the Image-Guided Therapy business segment. This is an area in the hospital where actually a lot of development is still taking place. Minimally invasive surgery is a surgery of the future. Actually more therapy areas being developed where this can be applied. So actually, to develop that, you do a lot together with customers. So, if you look to our IGT business and the platform that we have developed, the Azurion platform, which is the leading system, more than 40% market share, actually, that's a very close collaboration with our customers. So, we have developed that out of the business, and we continue to develop that. Now we put the best in that solution from hardware, from software and from services. So, actually, we pull from across Philips the best of technologies to actually then make it the most useful, impactful application for the practitioners to use every day, but then also for the hospital to do in an efficient way. That's in IGT. But the same we can say for hospital patient monitoring, another very important business where we have a lot of opportunity where we develop the next generation of platform [MX] (ph) 7500, together with the surveillance solution, that actually has developed a lot in collaboration with our customers. So, yes, we will still do some breakthrough out of the corporate research, but more we will do in the businesses to gear up that it's really specific for the segment that we play in and therefore yield more impact and more return.

That's very helpful. Thank you very much.

Thank you. [Operator Instructions] We will now go to our next question. And your next question comes from the line of Ed Ridley-Day from Redburn. Please go ahead. Your line is open.

Good morning. Thank you. First question, a follow-up on the order book. If you could give us the year-end book-to-bill, that would be helpful. And how are you thinking about order book progression this year that was also coming off the 8%, obviously, decline year-on-year in the fourth quarter? And so, the related second question there is, can you actually define how much of that year-on-year decline was due to the one-time reorganization of the order book? I think that would help everyone if you could give that clarity. And I also had a follow-up on the 10% '23 to '25 Sleep & Respiratory growth assumption. Not so much for this year, but what does that really assume for '24, '25? Are you assume -- what -- are we in a position to make an assumption there given that we do not know the full outcome of the consent decree? That would be helpful if you could speak to that. Thank you.

Yes. So, let me start first with the book-to-bill. It was about 1.14, so again, more bookings and billings. The overall cancellation impact is about slightly more than 8%. So, if you take out the impact of the cancellation as well as the normalization due to COVID, because in the Connected Care segment, you see the 10% decline, and that's principally because of the COVID demand that came in last year. So -- the impact of both of these put together is more than the 8%. So, it would be roughly a kind of 1% growth. I think we have a lot of questions on the order book, and I'd like to clarify what we also showed on the slides earlier, that we start the year with a very, very good coverage for sales in 2023. You've seen in MR, we have 30% higher coverage in IGT and patient monitoring, and we didn't have it on the slide. But also in Ultrasound, we have more than 20% better coverage. So, the coverage for this year is actually in a very good space. Then, coming to your question on the SRC assumption, you kind of had answered the question a bit. Till we know the outcome of the consent decree, putting a year-by-year guidance becomes a bit premature. So, I think as Roy mentioned at the start, we are assuming a low single-digit growth this year, and then we will come with more clear guidance on the intermittent years as we have clarity around the consent decree.

Thank you, Abhijit, for that. And just a quick follow-up on the capital allocation. You highlighted, obviously, some thought around the buyback. Can you confirm whether you're going to go ahead with that? Or when might we hear some further thoughts on the buyback commitment, obviously, considering the broad cash demand that you have this year?

Yes. So, the existing buyback, we have, as you know, executed in the -- through forward. So, those will get due this year, and we will execute on that. So, there is no change in the commitment there. So that's basically where we stand on that.

Fair enough. Thank you.

Thanks, Ed.

Thank you. We will now take our next question. And your next question comes from the line of Robert Davies from Morgan Stanley. Please go ahead. Your line is open.

Yes. Thanks for taking my questions. My first one was just on, I think, your bridge you had for 2022 to 2025. So, you had in amongst -- I think it was pricing mix in COGS of 4% to 5% increase. Just be curious there, how much of that is underpinned by what you can see in your current order backlog versus what you're intending to put through effectively in your book-to-bill part of your business? And then, my second question was just around the Personal Health, just around the consumer outlook there. But just curious in terms of what you're seeing in -- I know you mentioned sort of more difficult comp moving into the first quarter, but just on an underlying basis, just be curious to see how customer behavior is sort of feeding into growth trends there through the early part of the year. And then, on the last one, was just around the sort of post 2025 outlook. So, you put sort of mid- to high-teens. In simple terms, how do you get there? I mean that's obviously well above anything Philips has done before. And I think probably, if anything, the margin targets have always been a bit more stretched than the growth targets for Philips. What would need to change really between now and '25 to turn this into a mid- to high-teens margin business? Thank you.

Should I start with the first one, then you...

Yes.

So, for the pricing mix, actually, if you look, most of that is underpinned by the plans we shared with you. Part of that is pricing. And I think I also explained that the pricing that we are seeing now in the order book will start flowing into the P&L from the second half of this year. There is, of course, some assumptions on the savings that we will do in our bill of material. That is always an outlook that we take. But we do see that, let's say, in the medium term, the huge spike that we saw in prices in the last couple of years, that will start easing. So, I think most of that we have taken in. Is it 100% underpinned? Obviously not, because a lot changes between now and 2025, but it gives us a good level of confidence on the basis of which we have presented that plan. You want to take the one on consumer demand?

Yes. So, if you look to the consumer demand, we -- and we saw it also in Q4, there is still quite some pressure on consumer demand globally given the macroeconomic environment consumers have to deal with. Also, we saw some particular pain in China. Now we expect that in the -- especially early part of 2023 to continue. We do expect that it will ease towards more in the back of 2023. So, we also expect a return to growth in Personal Health, as we have shown to you in due course of this year, will be not yet as strong as the health system side, but we expect a gradual recovery as we work through the global crisis and then also the inflationary impact on the consumer side. So that's the outlook there. Then in terms of your post-2025 question, I think that also really goes to the heart of what we present today in which we say, actually, we have a very compelling and strong portfolio. But we need to go and differentiate it with our approach to actually extract the maximum value. Now, if you saw to the four buckets that I presented, the first bucket, accelerate growth and profit is a bucket that consists out of IGT, Ultrasound, HPM, PH, all of those businesses have been already in the range that you allude to, are 70% -- close to 70% of our sales and actually dialing them up fast actually will get us very strongly into that range. Now then, it's also about how we can scale informatics, where we have been investing. It becomes a really very interesting differentiator for us also with our customers. And we have the plan that we presented to you in which actually you see informatics really starting to contribute. Then we know that we have to improve our margins in imaging. Now that's very much on conversion of the order book, so supply chain, operational excellence, but also serves as pull-through. And then, ultimately, it's the SRC part where if we get back into restoring our business and indeed, that is also what we expect beyond 2025, that, in totality, actually should allow us to get into that range. So, actually, we have been, releasing in our plan, looking at the strengths that we have across the portfolio and what needs to be done in each segment, in particular, to actually attract the most value.

That's great. Thank you for your answers.

Thank you. Gentlemen, that was the last question. Please continue.

It was the last question. Roy?

Okay. Then, let me thank you for being with us today. It was a bit of an extensive session, but it was an important session, because we presented to you how we will bring back Philips where it belongs. I want to close in saying that we are realistic in the situation that we are facing. But we are very confident in the plan that we presented to you, and we are extremely excited about the future that Philips has with all the actions that we are undertaking. So, I want to thank you again for dialing in and look forward to talk to you soon when I'm on the road with all of you. Thank you so much, and wish you a great day.